Timosin alpha-1 immunomodulating properties

The aim of review. To present modern data on the mechanism of action and clinical utilization of immunomodulating agent «Timosin alpha-1».Original positions of the report. Timosin alpha1 is 28-base acetylated polypeptide, that effectively modulates human immune system and has direct action on the ce...

Full description

Saved in:
Bibliographic Details
Main Author: M. V. Mayevskaya
Format: Article
Language:Russian
Published: Gastro LLC 2009-02-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/1595
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860283769094144
author M. V. Mayevskaya
author_facet M. V. Mayevskaya
author_sort M. V. Mayevskaya
collection DOAJ
description The aim of review. To present modern data on the mechanism of action and clinical utilization of immunomodulating agent «Timosin alpha-1».Original positions of the report. Timosin alpha1 is 28-base acetylated polypeptide, that effectively modulates human immune system and has direct action on the cells infected by virus that allows to talk of its «double» mechanism of action. Immunomodulating effect of Timosin alpha-1 consists in increase of natural killer cells number, CD4 and CD8 by stimulation of stem cells differentiation and decrease of T-cells apoptosis, and also in driving of immune response to Th1 subtype by increase of Th1 cytokines (IL-2, IFN) amount and decreases of amount of Th2 cytokines (IL-4, IL-10). Direct antiviral mechanism of Timosin alpha-1 consists in increase of expression of major histocompatibility complex molecules of the 1st class on infected cells and direct suppression of virus replication, and also in elevation of endocellular level of glutathione. Combination of Timosin alpha-1 and interferon-a (IFN-a) induces substantial increase of IL-2 level and blocks elevation of IL-10 level invoked by IFN-a that can be successfully utilized in chronic hepatitis B (CHB) treatment. Results of metaanalysis of 4 randomized controlled studies in which efficacy of Timosin alpha-1 and IFNб was compared in treatment of CHB (total number of patients – 199) were published. It is shown, that Timosin alpha-1 efficacy is increased eventually and is more pronounced at the end of monitoring period after termination of therapy. According to original studies The Asian-Pacific association for the study of the liver (APASL) included Timosin alpha-1 in the list of immunomodulating agents for CHB treatment besides standard and pegilated interferon-a (PEG-IFN-a). Efficacy of Timosin alpha-1 was demonstrated in the treatment of one of the most difficult groups of patients with persistent hepatitis C virus infection – non-responders at combined treatment by interferon and ribavirin. Timosin alpha-1 can be applied at immune antineoplastic therapy, in particular in treatment of hepatocellular carcinoma which is related to a final stage of persistent infection of hepatitis B and C viruses, that, as a rule, develops on a background of liver cirrhosis and in Caucasian patients.Conclusion. Timosin alpha-1 is successfully applied in clinical practice in treatment of chronic viral hepatites B and C, as antineoplastic immunomodulating drug and requires further active studies.
format Article
id doaj-art-610a3c85780c4b2098b3ad9bc22b25b6
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2009-02-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-610a3c85780c4b2098b3ad9bc22b25b62025-02-10T16:14:30ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732009-02-0119128341101Timosin alpha-1 immunomodulating propertiesM. V. Mayevskaya0Московская медицинская академия им. И. М. СеченоваThe aim of review. To present modern data on the mechanism of action and clinical utilization of immunomodulating agent «Timosin alpha-1».Original positions of the report. Timosin alpha1 is 28-base acetylated polypeptide, that effectively modulates human immune system and has direct action on the cells infected by virus that allows to talk of its «double» mechanism of action. Immunomodulating effect of Timosin alpha-1 consists in increase of natural killer cells number, CD4 and CD8 by stimulation of stem cells differentiation and decrease of T-cells apoptosis, and also in driving of immune response to Th1 subtype by increase of Th1 cytokines (IL-2, IFN) amount and decreases of amount of Th2 cytokines (IL-4, IL-10). Direct antiviral mechanism of Timosin alpha-1 consists in increase of expression of major histocompatibility complex molecules of the 1st class on infected cells and direct suppression of virus replication, and also in elevation of endocellular level of glutathione. Combination of Timosin alpha-1 and interferon-a (IFN-a) induces substantial increase of IL-2 level and blocks elevation of IL-10 level invoked by IFN-a that can be successfully utilized in chronic hepatitis B (CHB) treatment. Results of metaanalysis of 4 randomized controlled studies in which efficacy of Timosin alpha-1 and IFNб was compared in treatment of CHB (total number of patients – 199) were published. It is shown, that Timosin alpha-1 efficacy is increased eventually and is more pronounced at the end of monitoring period after termination of therapy. According to original studies The Asian-Pacific association for the study of the liver (APASL) included Timosin alpha-1 in the list of immunomodulating agents for CHB treatment besides standard and pegilated interferon-a (PEG-IFN-a). Efficacy of Timosin alpha-1 was demonstrated in the treatment of one of the most difficult groups of patients with persistent hepatitis C virus infection – non-responders at combined treatment by interferon and ribavirin. Timosin alpha-1 can be applied at immune antineoplastic therapy, in particular in treatment of hepatocellular carcinoma which is related to a final stage of persistent infection of hepatitis B and C viruses, that, as a rule, develops on a background of liver cirrhosis and in Caucasian patients.Conclusion. Timosin alpha-1 is successfully applied in clinical practice in treatment of chronic viral hepatites B and C, as antineoplastic immunomodulating drug and requires further active studies.https://www.gastro-j.ru/jour/article/view/1595timosin alpha-1ifn-apeg-ifn-ahepatites bc viruseshepatocellular carcinomat-helper cells of the 1st typet-helper cells of the 2nd typeimmunomodulating therapy
spellingShingle M. V. Mayevskaya
Timosin alpha-1 immunomodulating properties
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
timosin alpha-1
ifn-a
peg-ifn-a
hepatites b
c viruses
hepatocellular carcinoma
t-helper cells of the 1st type
t-helper cells of the 2nd type
immunomodulating therapy
title Timosin alpha-1 immunomodulating properties
title_full Timosin alpha-1 immunomodulating properties
title_fullStr Timosin alpha-1 immunomodulating properties
title_full_unstemmed Timosin alpha-1 immunomodulating properties
title_short Timosin alpha-1 immunomodulating properties
title_sort timosin alpha 1 immunomodulating properties
topic timosin alpha-1
ifn-a
peg-ifn-a
hepatites b
c viruses
hepatocellular carcinoma
t-helper cells of the 1st type
t-helper cells of the 2nd type
immunomodulating therapy
url https://www.gastro-j.ru/jour/article/view/1595
work_keys_str_mv AT mvmayevskaya timosinalpha1immunomodulatingproperties